NCT06891508 (PLACENTOMICS) is a NA clinical trial of Venous blood sampling in Preterm Birth, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT06891508?

NCT06891508 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT06891508?

Interventions in NCT06891508: Venous blood sampling, Tissues sampling, Umbilical cord blood sampling.

What condition does NCT06891508 study?

NCT06891508 studies Preterm Birth.

Is NCT06891508 still recruiting?

NCT06891508 is currently active, enrolled. Last updated 24 March 2025.

Last reviewed 2025-03-24 · How we verify

NCT06891508: PLACENTOMICS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Placental Secretome as a Therapeutic Tool to Prevent Inflammation-induced Preterm Birth

Active, enrolled NA Last updated 24 March 2025

What this trial tests

NA trial testing Venous blood sampling in Preterm Birth in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 March 2025

Primary endpoint
20 March 2026

20 March 2028

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	60
Start date	11 March 2025
Primary completion	20 March 2026
Estimated completion	20 March 2028
Sites	1 location across Italy

Drugs / interventions tested

Venous blood sampling
Tissues sampling
Umbilical cord blood sampling — full drug profile →

Conditions studied

Preterm Birth — all drugs for Preterm Birth →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, female only, with Preterm Birth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preterm birth complicates 10% of all pregnancies and is the leading cause of perinatal morbidity and mortality worldwide. Intra-amniotic inflammation (IAI) and chorioamnionitis are well-established causes of PTB; however, a treatable infectious trigger is identified in only 50% of cases.In sterile IAI and/or preterm premature rupture of membranes (pPROM), there are currently no effective therapeutic options to reduce inflammation, promote amniotic sac healing, and prevent preterm birth. Growing evidence suggests that the secretome of mesenchymal stem cells (MSC) exhibits immunomodulatory and tissue-regenerative properties, making it a promising therapeutic tool for inflammatory disorders. Specifically, the conditioned medium from human amniotic mesenchymal stromal cells (CM-hAMSC) has been successfully used to treat various preclinical inflammatory disease models. The aims of this study will be:1) to evaluate the activation of the NLRP3 inflammasome in hAM cells and peripheral blood mononuclear cells (PBMCs) from women with PTB. 2)To investigate the effect of CM-hAMSC on NLRP3 activation induced by lipopolysaccharide (LPS) and nigericin in cultured human amniotic epithelial cells (hAECs), amniotic mesenchymal stromal cells (hAMSCs), and PBMCs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Venous blood sampling

Trials testing the same drug.

NCT07319104 — Liquid Biopsy in Early Colorectal Lesions · not yet recruiting
NCT05090215 — Supervised Exercise for Post-surgery Colorectal Cancer Patients · NA · completed
NCT04907773 — Evaluation of a Blood Potassium Measurement Device From Capillary Samples (ALPHA) · NA · completed
NCT04154163 — Appropriate Dosing to Optimise Personalised Cancer Treatments · completed

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

NCT07265583 — Early Prediction of Lung Injury in Preterm Infants Score · recruiting
NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
NCT07192393 — Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocoliti · recruiting
NCT06826859 — Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH) · Phase 1, PHASE2 · recruiting
NCT07231432 — Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India · NA · active not recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06891508 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 24 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06891508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing